MCF Advisors LLC Acquires 182 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

MCF Advisors LLC raised its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 107.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 351 shares of the company’s stock after purchasing an additional 182 shares during the quarter. MCF Advisors LLC’s holdings in GeneDx were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in WGS. Rhumbline Advisers increased its position in shares of GeneDx by 8,096.4% during the 2nd quarter. Rhumbline Advisers now owns 18,360 shares of the company’s stock valued at $480,000 after purchasing an additional 18,136 shares during the last quarter. American Century Companies Inc. boosted its stake in GeneDx by 36.1% during the second quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after buying an additional 4,573 shares during the period. Renaissance Technologies LLC bought a new position in GeneDx during the second quarter valued at $2,362,000. Cubist Systematic Strategies LLC raised its stake in shares of GeneDx by 573.5% in the second quarter. Cubist Systematic Strategies LLC now owns 76,701 shares of the company’s stock valued at $2,005,000 after acquiring an additional 65,312 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in shares of GeneDx by 124.9% in the 2nd quarter. Squarepoint Ops LLC now owns 59,949 shares of the company’s stock worth $1,567,000 after acquiring an additional 33,293 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Stock Up 1.9 %

NASDAQ:WGS opened at $75.77 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm has a market cap of $2.08 billion, a PE ratio of -24.36 and a beta of 2.02. The company has a 50-day moving average of $77.59 and a 200 day moving average of $55.94. GeneDx Holdings Corp. has a 1-year low of $2.85 and a 1-year high of $98.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s quarterly revenue was up 44.3% on a year-over-year basis. During the same period last year, the firm earned ($0.82) earnings per share. As a group, research analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 35,506 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the completion of the transaction, the chief financial officer now owns 2,472 shares in the company, valued at $231,923.04. The trade was a 93.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Katherine Stueland sold 2,154 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total value of $143,456.40. Following the sale, the chief executive officer now owns 105,426 shares of the company’s stock, valued at approximately $7,021,371.60. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,229,965 shares of company stock valued at $93,006,163. Corporate insiders own 27.30% of the company’s stock.

Analyst Upgrades and Downgrades

WGS has been the topic of several analyst reports. The Goldman Sachs Group upped their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company raised their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. TD Cowen upped their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Finally, Craig Hallum lifted their target price on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.